Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

HRTXHERON THERAPEUTICS, INC. /DE/

Nasdaq · CIK 0000818033
Filer categoryAccelerated filer
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts367

Identity from submissions API

NameHERON THERAPEUTICS, INC. /DE/
CIK0000818033
TickersHRTX
ExchangesNasdaq
Entity typeoperating
CategoryAccelerated filer
SIC2834 Pharmaceutical Preparations
EIN942875566
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone8582514400
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • AP PHARMA INC /DE/ (2001-11-13T05:00:00.000Z → 2014-01-07T05:00:00.000Z)
  • ADVANCED POLYMER SYSTEMS INC /DE/ (1994-02-01T05:00:00.000Z → 2001-04-06T04:00:00.000Z)
Business address
4242 CAMPUS POINT COURT, SUITE 200
SAN DIEGO
CA
92121
CA
Mailing address
4242 CAMPUS POINT COURT, SUITE 200
SAN DIEGO
CA
92121
CA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

1528 filing rows loaded from submissions recent; extra archives: CIK0000818033-submissions-001.json (527 filings, 1994-02-01 to 2011-06-29).

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 DFAN14A SOLICITING MATERIAL PURSUANT TO 240.14A-12 0001213900-26-120019 001-33221 261554908 34 126227
2026-11-10 4 4 0001193125-26-454742 8532
2026-11-09 DEFA14A DEFA14A 0001193125-26-453822 001-33221 261536922 34 663131
2026-11-09 10-Q 10-Q 0001193125-26-452759 001-33221 261534038 34 10783949 1 1
2026-11-09 DEFA14A DEFA14A 0001193125-26-452725 001-33221 261533961 34 2466232
2026-11-09 8-K 8-K 2.02,9.01 0001193125-26-452721 001-33221 261533945 34 514082 1 1
2026-11-09 8-K 8-K 1.01,3.03,7.01,9.01 0001193125-26-452672 001-33221 261533837 34 2954495 1 1
2026-11-03 4 4 0001193125-26-444851 13654
2026-11-03 4 4 0001193125-26-444847 13477
2026-11-03 4 4 0001193125-26-444842 13525
2026-11-03 4 4 0001193125-26-444831 8622
2026-10-27 S-8 S-8 0001193125-26-434429 333-299658 261491390 33 631015 1 1
2026-10-21 4 4 0001193125-26-427545 8448
2026-10-21 4 4 0001193125-26-427542 8496
2026-10-21 4 4 0001193125-26-427524 8546
2026-09-29 8-K 8-K 1.01,9.01 0001193125-26-407728 001-33221 261424640 34 198990 1 1
2026-08-14 8-K 8-K 1.01,3.03,9.01 0001193125-26-352403 001-33221 261282509 34 231381 1 1
2026-08-10 4 4 0001193125-26-341528 8532
2026-08-10 10-Q 10-Q 0001193125-26-341301 001-33221 261256299 34 10756010 1 1
2026-08-10 8-K 8-K 2.02,9.01 0001193125-26-341300 001-33221 261256292 34 582349 1 1
2026-08-03 4 4 0001193125-26-329848 7262
2026-08-03 4 4 0001193125-26-329804 13525
2026-08-03 4 4 0001193125-26-329720 13477
2026-08-03 4 4 0001193125-26-329694 10919
2026-07-20 4 4 0001193125-26-308958 7179
2026-07-20 4 4 0001193125-26-308922 8496
2026-07-20 4 4 0001193125-26-308887 8448
2026-06-25 8-K 8-K 3.01,9.01 0001193125-26-282988 001-33221 261122836 34 204678 1 1
2026-06-17 4 4 0001193125-26-273552 8526
2026-06-16 8-K 8-K 5.07 0001193125-26-272388 001-33221 261094170 34 265766 1 1
2026-06-08 4 4 0001193125-26-260931 7214
2026-06-02 8-K 8-K 8.01,9.01 0001193125-26-253851 001-33221 261057688 34 216854 1 1
2026-05-13 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000919574-26-002913 005-39444 26971197 34 12066
2026-05-11 10-Q 10-Q 0001193125-26-215755 001-33221 26960931 34 8433482 1 1
2026-05-11 8-K 8-K 2.02,9.01 0001193125-26-215752 001-33221 26960922 34 509767 1 1
2026-05-07 4 4 0001193125-26-211230 7177
2026-05-04 4 4 0001193125-26-203374 7263
2026-05-04 4 4 0001193125-26-203344 10806
2026-05-04 4 4 0001193125-26-203272 10944
2026-05-04 4 4 0001193125-26-203196 11039
2026-04-30 ARS ARS 0001193125-26-196314 001-33221 26923238 34 923325
2026-04-30 DEFA14A DEFA14A 0001193125-26-196311 001-33221 26923235 34 580562
2026-04-30 DEF 14A DEF 14A 0001193125-26-196306 001-33221 26923216 34 4257394 1 1
2026-04-21 4 4 0001193125-26-165591 7138
2026-04-21 4 4 0001193125-26-165365 7181
2026-04-21 4 4 0001193125-26-165304 7282
2026-04-20 PRE 14A PRE 14A 0001193125-26-164270 001-33221 26876015 34 5707964 1 1
2026-04-06 4 4 0001193125-26-144196 7455
2026-04-06 8-K 8-K 5.02,9.01 0001193125-26-142947 001-33221 26839644 34 864388 1 1
2026-03-27 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000102909-26-001421 005-39444 26801464 34 7373
2026-02-26 10-K 10-K 0001193125-26-073515 001-33221 26681789 34 16571126 1 1
2026-02-26 8-K 8-K 2.02,9.01 0001193125-26-073502 001-33221 26681764 34 542969 1 1
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001600136-26-000002 005-39444 26639861 34 14101
2026-02-03 4 4 0001193125-26-034633 8555
2026-02-03 4 4 0001193125-26-034632 25957
2026-02-03 4 4 0001193125-26-034631 25951
2026-02-03 4 4 0001193125-26-034630 8460
2026-02-03 4 4 0001193125-26-034629 26011
2026-02-03 4 4 0001193125-26-034628 4806
2026-02-03 4 4 0001193125-26-034627 8508
2026-02-03 4 4 0001193125-26-034626 25948
2026-02-03 4 4 0001193125-26-034625 8503
2026-02-03 4 OWNERSHIP DOCUMENT 0000921895-26-000200 6456
2026-02-03 4 4 0001193125-26-034492 6946
2026-02-03 4 4 0001193125-26-034491 7001
2026-02-03 4 4 0001193125-26-034490 7041
2026-01-30 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000102909-26-000207 005-39444 26582382 34 7173
2026-01-20 4 4 0001193125-26-016451 7001
2026-01-20 4 4 0001193125-26-016423 6946
2026-01-20 4 4 0001193125-26-016413 7045
2026-01-09 8-K 8-K 7.01,9.01 0001193125-26-008631 001-33221 26522185 34 238029 1 1
2025-11-26 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001600136-25-000011 005-39444 251525493 34 13955
2025-11-12 4 4 0001193125-25-276244 7128
2025-11-07 3 3 0001193125-25-271244 26387
2025-11-04 4 4 0001193125-25-264044 7002
2025-11-04 4 4 0001193125-25-264039 6947
2025-11-04 4 4 0001193125-25-264032 7042
2025-11-04 10-Q 10-Q 0001193125-25-263618 001-33221 251446510 34 10419869 1 1
2025-11-04 8-K 8-K 2.02,9.01 0001193125-25-263617 001-33221 251446501 34 603289 1 1
2025-10-30 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000102909-25-000136 005-39444 251434778 34 6478
2025-10-29 8-K 8-K 5.02,7.01,9.01 0001193125-25-256300 001-33221 251429955 34 213220 1 1
2025-10-21 4 4 0001193125-25-244582 27443
2025-10-21 4 4 0001193125-25-244560 27388
2025-10-21 4 4 0001193125-25-244520 27490
2025-10-17 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0000902664-25-004460 005-39444 251401744 34 11101
2025-10-17 4 xslF345X05/ownership.xml 0000902664-25-004459 12746
2025-10-15 8-K 8-K 5.07,9.01 0001193125-25-240253 001-33221 251394921 34 213331 1 1
2025-09-19 DEF 14A DEF 14A 0001193125-25-209064 001-33221 251326836 34 1242281
2025-09-16 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-002980 333-290143 251318722 33 1955
2025-09-16 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-002979 333-290142 251318721 33 1955
2025-09-12 CORRESP filename1.htm 0000950170-25-114551 20368
2025-09-12 CORRESP filename1.htm 0000950170-25-114548 20676
2025-09-11 UPLOAD filename1.pdf 0000000000-25-009896 333-290142 40346
2025-09-11 UPLOAD filename1.pdf 0000000000-25-009895 333-290143 40349
2025-09-09 S-3 S-3 0000950170-25-113834 333-290143 251304035 33 1475644 1 1
2025-09-09 S-3 S-3 0000950170-25-113830 333-290142 251303995 33 1573629 1 1
2025-09-09 PRE 14A PRE 14A 0000950170-25-113827 001-33221 251303958 34 377169
2025-08-28 8-K 8-K 1.01,9.01 0000950170-25-112048 001-33221 251274494 34 198766 1 1
2025-08-15 8-A12B 8-A12B 0000950170-25-109236 001-33221 251222441 34 67533
2025-08-15 8-K 8-K 1.01,3.03,5.03,8.01,9.01 0000950170-25-109234 001-33221 251222434 34 991249 1 1
2025-08-12 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0000902664-25-003536 005-39444 251208296 34 856929
2025-08-12 4 xslF345X05/ownership.xml 0000902664-25-003535 14301
2025-08-12 4 OWNERSHIP DOCUMENT 0000921895-25-002160 10746
2025-08-12 8-K 8-K 1.01,5.03,8.01,9.01 0000950170-25-107416 001-33221 251207487 34 3525515 1 1
2025-08-12 8-K 8-K 1.01 0000950170-25-107404 001-33221 251207334 34 192031 1 1
2025-08-08 10-Q 10-Q 0000950170-25-105475 001-33221 251196219 34 9934990 1 1
2025-08-08 8-K 8-K 1.01,2.02,2.03,3.02,8.01,9.01 0000950170-25-105474 001-33221 251196218 34 695778 1 1
2025-08-04 4 4 0000950170-25-102161 7002
2025-08-04 4 4 0000950170-25-102158 7393
2025-08-04 4 4 0000950170-25-102150 7042
2025-07-22 4 4 0000950170-25-097503 7002
2025-07-22 4 4 0000950170-25-097498 6947
2025-07-22 4 4 0000950170-25-097488 7046
2025-06-18 8-K 8-K 5.07 0000950170-25-087555 001-33221 251054598 34 240406 1 1
2025-06-17 4 4 0000950170-25-087534 7025
2025-06-09 4 4 0000950170-25-084006 7080
2025-05-07 4 4 0000950170-25-065310 5477
2025-05-06 S-8 S-8 0000950170-25-064589 333-287008 25918145 33 500554 1 1
2025-05-06 10-Q 10-Q 0000950170-25-063971 001-33221 25915280 34 7896236 1 1
2025-05-06 8-K 8-K 2.02,9.01 0000950170-25-063973 001-33221 25915276 34 466902 1 1
2025-05-06 8-K 8-K 8.01,9.01 0000950170-25-063967 001-33221 25915241 34 223859 1 1
2025-05-02 4 4 0000950170-25-063065 7001
2025-05-02 4 4 0000950170-25-063063 6946
2025-05-02 4 4 0000950170-25-063061 7041
2025-04-30 DEFA14A DEFA14A 0000950170-25-060884 001-33221 25893582 34 1218278
2025-04-30 ARS ARS 0000950170-25-060883 001-33221 25893577 34 743166
2025-04-30 DEF 14A DEF 14A 0000950170-25-060882 001-33221 25893570 34 4847132 1 1
2025-04-29 4 4 0000950170-25-059775 6428
2025-04-29 3 3 0000950170-25-059774 26260
2025-04-29 8-K 8-K 5.02,9.01 0000950170-25-059479 001-33221 25882131 34 235243 1 1
2025-04-22 4 4 0000950170-25-056495 7001
2025-04-22 4 4 0000950170-25-056492 6946
2025-04-22 4 4 0000950170-25-056488 7045
2025-04-03 4 4 0000950170-25-050677 7120
2025-02-27 10-K 10-K 0000950170-25-028374 001-33221 25673074 34 14260633 1 1
2025-02-27 8-K 8-K 2.02,9.01 0000950170-25-028372 001-33221 25673072 34 483555 1 1
2025-02-20 8-K 8-K 1.01,9.01 0000950170-25-023958 001-33221 25644543 34 286103 1 1
2025-02-04 4/A 4/A 0000950170-25-013789 7102
2025-02-04 4/A 4/A 0000950170-25-013780 8539
2025-02-04 4/A 4/A 0000950170-25-013770 7117
2025-02-04 4/A 4/A 0000950170-25-013756 7121
2025-02-04 4/A 4/A 0000950170-25-013741 7131
2025-02-04 4/A 4/A 0000950170-25-013728 7132
2025-02-04 4 4 0000950170-25-013045 7656
2025-02-04 4 4 0000950170-25-013044 7608
2025-02-04 4 4 0000950170-25-013042 7706
2025-02-03 4 4 0000950170-25-012119 7027
2025-02-03 4 4 0000950170-25-012107 22348
2025-02-03 4 4 0000950170-25-012101 22340
2025-02-03 4 4 0000950170-25-012096 22354
2025-02-03 4 4 0000950170-25-012094 22355
2025-02-03 4 4 0000950170-25-012043 23754
2025-01-22 4 4 0000950170-25-007557 7160
2025-01-22 4 4 0000950170-25-007549 7008
2025-01-22 4 4 0000950170-25-007545 7259
2024-12-23 8-K 8-K 7.01,9.01 0000950170-24-139569 001-33221 241573586 34 224058 1 1
2024-12-03 8-K 8-K 8.01 0000950170-24-132874 001-33221 241523697 34 171087 1 1
2024-11-12 SC 13G HERON THERAPEUTICS, INC. 0000902664-24-006401 005-39444 241444204 34 75719
2024-11-12 10-Q 10-Q 0000950170-24-124698 001-33221 241443892 34 7171685 1 1
2024-11-12 8-K 8-K 2.02,9.01 0000950170-24-124626 001-33221 241443561 34 367855 1 1
2024-11-08 SC 13G us4277461020_110824.txt 0002012383-24-003510 005-39444 241439646 34 13872
2024-11-06 4 4 0000950170-24-122084 7150
2024-11-05 3 3 0000950170-24-121242 14346
2024-11-04 8-K 8-K 5.02,7.01 0000950170-24-120902 001-33221 241424633 34 197176 1 1
2024-10-24 SC 13G us4277461020_102424.txt 0002012383-24-002188 005-39444 241392059 34 13860
2024-10-21 4 4 0000950170-24-115927 6967
2024-10-21 4 4 0000950170-24-115925 7015
2024-10-21 4 4 0000950170-24-115920 7065
2024-08-06 S-8 S-8 0000950170-24-091916 333-281293 241179945 33 706943 1 1
2024-08-06 10-Q 10-Q 0000950170-24-091764 001-33221 241179108 34 6779919 1 1
2024-08-06 8-K 8-K 2.02,9.01 0000950170-24-091769 001-33221 241179097 34 357230 1 1
2024-07-22 4 4 0000950170-24-085096 7065
2024-07-22 4 4 0000950170-24-085092 7014
2024-07-22 4 4 0000950170-24-085089 6967
2024-07-02 8-K 8-K 7.01,9.01 0000950170-24-080026 001-33221 241093007 34 196261 1 1
2024-06-18 8-K 8-K 5.02,5.03,5.07,9.01 0000950170-24-074952 001-33221 241052487 34 265172 1 1
2024-06-17 4 4 0000950170-24-074168 7045
2024-06-07 4 4 0000950170-24-070250 7092
2024-05-31 SC 13D/A AMENDMENT NO. 3 TO THE SCHEDULE 13D 0000921895-24-001343 005-39444 241008289 34 67364
2024-05-29 8-K 8-K 7.01,9.01 0000950170-24-065636 001-33221 24994067 34 197289 1 1
2024-05-07 10-Q 10-Q 0000950170-24-053964 001-33221 24919713 34 6330307 1 1
2024-05-07 8-K 8-K 2.02,9.01 0000950170-24-053963 001-33221 24919710 34 350756 1 1
2024-04-29 ARS ARS 0001140361-24-022885 001-33221 24889667 34 627687
2024-04-29 DEF 14A DEF 14A 0001140361-24-022881 001-33221 24889644 34 2970390
2024-04-19 4 4 0000950170-24-046134 21788
2024-04-19 PRE 14A PRE 14A 0001140361-24-020831 001-33221 24858959 34 2987683
2024-04-19 4 4 0000950170-24-046085 20484
2024-04-19 4 4 0000950170-24-046050 7064
2024-04-05 4 4 0000950170-24-042226 20602
2024-03-21 8-K 8-K 5.02 0001193125-24-073897 001-33221 24771861 34 145934 1 1
2024-03-12 10-K 10-K 0000950170-24-029951 001-33221 24742255 34 10567119 1 1
2024-03-12 8-K 8-K 2.02,9.01 0000950170-24-029926 001-33221 24742150 34 409301 1 1
2024-02-14 SC 13G/A greatpoint-hrtx123123a1.htm 0001172661-24-001524 005-39444 24639393 34 110524
2024-02-14 SC 13G/A SC 13G/A 0001104659-24-023728 005-39444 24638761 34 90759
2024-02-14 SC 13G/A deeptrack-hrtx123123a1.htm 0001172661-24-000924 005-39444 24632655 34 103088
2024-02-13 SC 13G/A SCHEDULE 13G/A 0001104659-24-021114 005-39444 24628542 34 13259
2024-02-06 SC 13G/A hero23a13.htm 0000038777-24-000015 005-39444 24599008 34 174062
2024-01-24 8-K 8-K 8.01,9.01 0001193125-24-013587 001-33221 24554280 34 168867 1 1
2024-01-19 4 FORM 4 SUBMISSION 0001209191-24-001982 7352
2024-01-19 4 FORM 4 SUBMISSION 0001209191-24-001981 7351
2024-01-19 4 FORM 4 SUBMISSION 0001209191-24-001980 8718
2024-01-19 4 FORM 4 SUBMISSION 0001209191-24-001979 7342
2024-01-19 4 FORM 4 SUBMISSION 0001209191-24-001978 7337
2024-01-19 4 FORM 4 SUBMISSION 0001209191-24-001977 7964
2024-01-19 4 FORM 4 SUBMISSION 0001209191-24-001976 8047
2024-01-19 4 FORM 4 SUBMISSION 0001209191-24-001975 7999
2024-01-19 4 FORM 4 SUBMISSION 0001209191-24-001974 8104
2024-01-16 4 FORM 4 SUBMISSION 0001209191-24-001626 13163
2024-01-11 8-K 8-K 1.01,9.01 0001193125-24-006600 001-33221 24529325 34 169246 1 1
2023-12-22 8-K 8-K 8.01 0001193125-23-302150 001-33221 231510224 34 146330 1 1
2023-12-21 8-K 8-K 5.02 0001193125-23-301337 001-33221 231506327 34 143051 1 1
2023-12-07 SC 13G/A FILING HERON THERAPEUTICS, INC. 0000019617-23-000588 005-39444 34 89985
2023-12-06 SC 13G/A us4277461020_120623.txt 0001306550-23-010470 005-39444 231470221 34 12611
2023-11-21 4 FORM 4 SUBMISSION 0001209191-23-056198 4802
2023-11-20 4 FORM 4 SUBMISSION 0001209191-23-055948 5124
2023-11-17 4 FORM 4 SUBMISSION 0001209191-23-055664 5177
2023-11-17 4 FORM 4 SUBMISSION 0001209191-23-055663 5081
2023-11-14 10-Q 10-Q 0000950170-23-063714 001-33221 231406433 34 7971076 1 1
2023-11-14 8-K 8-K 2.02,9.01 0000950170-23-063702 001-33221 231406184 34 462363 1 1
2023-10-17 4 FORM 4 SUBMISSION 0001209191-23-053030 18904
2023-09-06 424B3 424B3 0001193125-23-228822 333-274167 231237628 33 196627
2023-08-31 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2023-08-31 16:00:00 9999999995-23-002550 333-274167 231230482 33 1913
2023-08-30 CORRESP filename1.htm 0001193125-23-224255 6516
2023-08-28 UPLOAD filename1.pdf 0000000000-23-009456 40532
2023-08-24 4 FORM 4 SUBMISSION 0001209191-23-047180 5183
2023-08-23 S-3 S-3 0001193125-23-219106 333-274167 231197647 33 323938
2023-08-14 10-Q 10-Q 0000950170-23-042431 001-33221 231170460 34 9500750 1 1
2023-08-14 8-K 8-K 2.02,9.01 0000950170-23-042414 001-33221 231170191 34 506189 1 1
2023-08-01 D xslFormDX01/primary_doc.xml 06b 0001209191-23-043921 021-488462 231130952 33 12066
2023-07-25 4 OWNERSHIP DOCUMENT 0000921895-23-001721 9755
2023-07-25 3 OWNERSHIP DOCUMENT 0000921895-23-001720 6664
2023-07-25 SC 13D/A AMENDMENT NO. 2 TO THE SCHEDULE 13D 0000921895-23-001719 005-39444 231108691 34 74311
2023-07-24 8-K 8-K 1.01,3.02,5.02,7.01,9.01 0001193125-23-191942 001-33221 231103881 34 680652 1 1
2023-07-19 4 FORM 4 SUBMISSION 0001209191-23-042787 5562
2023-07-17 4 FORM 4 SUBMISSION 0001209191-23-042480 13174
2023-07-17 4 FORM 4 SUBMISSION 0001209191-23-042479 13082
2023-06-30 S-8 S-8 0001193125-23-180386 333-273059 231061744 33 276297
2023-06-23 3 FORM 3 SUBMISSION 0001209191-23-039402 9688
2023-06-23 8-K 8-K 5.02,9.01 0000950170-23-029646 001-33221 231037937 34 298606 1 1
2023-06-12 3 FORM 3 SUBMISSION 0001209191-23-036343 10364
2023-06-12 8-K 8-K 5.02,5.03,5.07,9.01 0000950170-23-027374 001-33221 231007228 34 498656 1 1
2023-05-24 4 FORM 4 SUBMISSION 0001209191-23-031910 5182
2023-05-11 10-Q 10-Q 0000950170-23-021237 001-33221 23911116 34 7075822 1 1
2023-05-11 8-K 8-K 2.02,9.01 0000950170-23-021213 001-33221 23910951 34 437231 1 1
2023-05-01 ARS ARS 0000950170-23-016047 001-33221 23870540 34 1564409
2023-05-01 DEF 14A DEF 14A 0000950170-23-016042 001-33221 23870503 34 5487693
2023-04-20 PRE 14A PRE 14A 0000950170-23-013675 001-33221 23833160 34 3090397
2023-04-20 8-K 8-K 5.02,9.01 0000950170-23-013583 001-33221 23831569 34 375096 1 1
2023-04-17 4 FORM 4 SUBMISSION 0001209191-23-024500 13173
2023-04-17 4 FORM 4 SUBMISSION 0001209191-23-024499 13121
2023-04-17 4 FORM 4 SUBMISSION 0001209191-23-024498 13082
2023-04-17 4 FORM 4 SUBMISSION 0001209191-23-024497 13156
2023-04-13 SC 13G greatpoint-hrtx041323.htm 0001172661-23-001684 005-39444 23817946 34 112891
2023-04-05 4 FORM 4 SUBMISSION 0001209191-23-023385 10905
2023-04-03 8-K 8-K 5.02,9.01 0000950170-23-011487 001-33221 23790883 34 385100 1 1
2023-03-29 10-K 10-K 0000950170-23-010603 001-33221 23775317 34 12638733 1 1
2023-03-23 8-K 8-K 2.02,9.01 0000950170-23-009489 001-33221 23756304 34 496588 1 1
2023-03-13 8-K 8-K 8.01,9.01 0000950170-23-007473 001-33221 23725924 34 302960 1 1
2023-03-06 8-K 8-K 8.01,9.01 0000950170-23-006139 001-33221 23707760 34 390961 1 1
2023-03-02 3 FORM 3 SUBMISSION 0001209191-23-014628 8431
2023-03-02 3 FORM 3 SUBMISSION 0001209191-23-014621 7804
2023-02-24 4 FORM 4 SUBMISSION 0001209191-23-012924 11417
2023-02-22 SC 13D/A AMENDMENT NO. 1 TO THE SCHEDULE 13D 0000921895-23-000593 005-39444 23653494 34 378596
2023-02-22 8-K 8-K 1.01,5.02,7.01,9.01 0001193125-23-044236 001-33221 23650663 34 346904 1 1
2023-02-15 SC 13G/A arrowmark-hrtx123122a2.htm 0001172661-23-001475 005-39444 23632208 34 54372
2023-02-14 SC 13G/A AMENDMENT NO. 3 0001214659-23-002397 005-39444 23628411 34 77586
2023-02-13 SC 13G/A SC 13G/A 0001193125-23-034205 005-39444 23614688 34 42010
2023-02-09 SC 13G/A SCHEDULE 13G/A 0001104659-23-016123 005-39444 23603369 34 13178
2023-02-08 3 OWNERSHIP DOCUMENT 0000921895-23-000348 13925
2023-02-08 3 OWNERSHIP DOCUMENT 0000921895-23-000347 7215
2023-02-06 SC 13D SCHEDULE 13D 0000921895-23-000284 005-39444 23588774 34 303133
2023-02-03 SC 13G/A us4277461020_020323.txt 0001306550-23-007834 005-39444 23586368 34 13556
2023-01-31 SC 13G/A hero22a121.htm 0000038777-23-000023 005-39444 23571459 34 209914
2023-01-23 SC 13G/A FILING HERON THERAPEUTICS, INC. 0000019617-23-000134 005-39444 34 90002
2023-01-20 4 FORM 4 SUBMISSION 0001209191-23-004304 6195
2023-01-20 4 FORM 4 SUBMISSION 0001209191-23-004303 5584
2023-01-20 4 FORM 4 SUBMISSION 0001209191-23-004302 6143
2023-01-20 4 FORM 4 SUBMISSION 0001209191-23-004301 6108
2023-01-20 4 FORM 4 SUBMISSION 0001209191-23-004299 6181
2023-01-17 4 FORM 4 SUBMISSION 0001209191-23-003564 14859
2023-01-17 4 FORM 4 SUBMISSION 0001209191-23-003563 14849
2023-01-17 4 FORM 4 SUBMISSION 0001209191-23-003562 13089
2023-01-17 4 FORM 4 SUBMISSION 0001209191-23-003561 13051
2023-01-17 4 FORM 4 SUBMISSION 0001209191-23-003560 14842
2023-01-10 SC 13G/A Heron_Therapeutics_Inc.txt 0000093751-23-000001 005-39444 23519686 34 8645
2023-01-09 8-K 8-K 2.02,7.01,9.01 0000950170-23-000458 001-33221 23516772 34 419516 1 1
2022-12-29 8-K 8-K 8.01,9.01 0000950170-22-027082 001-33221 221496439 34 301709 1 1
2022-12-20 4 FORM 4 SUBMISSION 0001209191-22-062192 7240
2022-12-20 4 FORM 4 SUBMISSION 0001209191-22-062191 7239
2022-12-20 4 FORM 4 SUBMISSION 0001209191-22-062188 7230
2022-12-20 4 FORM 4 SUBMISSION 0001209191-22-062187 7225
2022-12-20 4 FORM 4 SUBMISSION 0001209191-22-062184 7245
2022-11-08 10-Q 10-Q 0001564590-22-037047 001-33221 221369180 34 7994670 1 1
2022-11-08 8-K 8-K 2.02,9.01 0001564590-22-037038 001-33221 221368976 34 529194 1 1
2022-10-20 424B5 424B5 0001193125-22-265939 333-267781 221321309 33 195693
2022-10-18 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2022-10-18 16:00:00 9999999995-22-003077 333-267781 221317152 33 1913
2022-10-17 4 FORM 4 SUBMISSION 0001209191-22-053836 13143
2022-10-17 4 FORM 4 SUBMISSION 0001209191-22-053835 13131
2022-10-17 4 FORM 4 SUBMISSION 0001209191-22-053834 13091
2022-10-17 4 FORM 4 SUBMISSION 0001209191-22-053832 13051
2022-10-17 4 FORM 4 SUBMISSION 0001209191-22-053827 13126
2022-10-13 CORRESP filename1.htm 0001193125-22-262254 7168
2022-10-13 UPLOAD filename1.pdf 0000000000-22-011246 40379
2022-10-07 S-3 S-3 0001193125-22-259613 333-267781 221300936 33 314653
2022-09-19 8-K 8-K 8.01,9.01 0001564590-22-031836 001-33221 221249427 34 7844296 1 1
2022-09-09 S-8 S-8 0001193125-22-241942 333-267352 221236105 33 201058
2022-08-19 SC 13G deeptrack-hrtx08092022.htm 0001172661-22-002028 005-39444 221180762 34 103269
2022-08-10 8-K 8-K 1.01,3.02,9.01 0001193125-22-217430 001-33221 221152421 34 621223 1 1
2022-08-09 10-Q 10-Q 0001564590-22-028599 001-33221 221146630 34 8003170 1 1
2022-08-09 8-K 8-K 2.02,9.01 0001564590-22-028597 001-33221 221146528 34 553994 1 1
2022-07-27 4 FORM 4 SUBMISSION 0001209191-22-043292 5620
2022-07-27 4 FORM 4 SUBMISSION 0001209191-22-043291 5568
2022-07-27 4 FORM 4 SUBMISSION 0001209191-22-043289 5530
2022-07-27 4 FORM 4 SUBMISSION 0001209191-22-043288 5603
2022-07-15 4 FORM 4 SUBMISSION 0001209191-22-042263 14858
2022-07-15 4 FORM 4 SUBMISSION 0001209191-22-042262 14847
2022-07-15 4 FORM 4 SUBMISSION 0001209191-22-042261 13091
2022-07-15 4 FORM 4 SUBMISSION 0001209191-22-042260 13051
2022-07-15 4 FORM 4 SUBMISSION 0001209191-22-042259 13126
2022-06-30 8-K 8-K 2.05,9.01 0001564590-22-024885 001-33221 221056608 34 232619 1 1
2022-06-14 8-K 8-K 7.01,9.01 0001564590-22-023137 001-33221 221013510 34 232364 1 1
2022-05-25 8-K 8-K 5.07 0001564590-22-021277 001-33221 22963328 34 216336 1 1
2022-05-09 10-Q 10-Q 0001564590-22-018877 001-33221 22905150 34 6654134 1 1
2022-05-09 8-K 8-K 2.02,9.01 0001564590-22-018871 001-33221 22905018 34 494395 1 1
2022-05-04 4 FORM 4 SUBMISSION 0001209191-22-027232 7010
2022-04-25 DEF 14A DEF 14A 0001564590-22-015345 001-33221 22847493 34 3694481
2022-04-15 4 FORM 4 SUBMISSION 0001209191-22-024523 13141
2022-04-15 4 FORM 4 SUBMISSION 0001209191-22-024522 13130
2022-04-15 4 FORM 4 SUBMISSION 0001209191-22-024521 13090
2022-04-15 4 FORM 4 SUBMISSION 0001209191-22-024520 13050
2022-04-15 4 FORM 4 SUBMISSION 0001209191-22-024519 13124
2022-04-14 PRE 14A PRE 14A 0001564590-22-014474 001-33221 22827666 34 3760247
2022-04-11 SC 13G/A Heron_Therapeutics_Inc.txt 0000093751-22-000491 005-39444 22819331 34 10562
2022-03-25 8-K 8-K 7.01,9.01 0001564590-22-011751 001-33221 22768327 34 1916982 1 1
2022-03-17 8-K 8-K 8.01,9.01 0001564590-22-010729 001-33221 22746906 34 219454 1 1
2022-02-28 10-K 10-K 0001564590-22-007618 001-33221 22689633 34 13043740 1 1
2022-02-28 8-K 8-K 2.02,9.01 0001564590-22-007608 001-33221 22689314 34 541277 1 1
2022-02-14 SC 13G/A SC 13G/A 0001104659-22-022825 005-39444 22632106 34 126885
2022-02-14 SC 13G/A AMENDMENT NO. 2 0001214659-22-002555 005-39444 22631041 34 77561
2022-02-14 SC 13G/A arrowmark-hrtx123121a1.htm 0001172661-22-000639 005-39444 22629429 34 54175
2022-02-14 SC 13G SC 13G 0001193125-22-040411 005-39444 22627242 34 39159
2022-02-11 SC 13G HERON_THERAPEUTICS_INC.txt 0000093751-22-000244 005-39444 22617243 34 10509
2022-02-10 SC 13G/A SCHEDULE 13G/A 0001104659-22-017739 005-39444 22609952 34 13173
2022-02-04 SC 13G/A SEC SCHEDULE 13G 0001678858-22-000298 005-39444 22591489 34 33152
2022-02-03 SC 13G/A hero21a11.htm 0000038777-22-000033 005-39444 22587908 34 212105
2022-02-01 SC 13G/A us4277461020_020122.txt 0000834237-22-004531 005-39444 22579981 34 13586
2022-01-24 SC 13G FILING HERON THERAPEUTICS, INC. 0000019617-22-000165 005-39444 34 90073
2022-01-14 4 FORM 4 SUBMISSION 0001209191-22-003364 13126
2022-01-14 4 FORM 4 SUBMISSION 0001209191-22-003362 13117
2022-01-14 4 FORM 4 SUBMISSION 0001209191-22-003361 13077
2022-01-14 4 FORM 4 SUBMISSION 0001209191-22-003360 13037
2022-01-14 4 FORM 4 SUBMISSION 0001209191-22-003358 13109
2021-12-23 4 FORM 4 SUBMISSION 0001209191-21-071173 4929
2021-12-23 4 FORM 4 SUBMISSION 0001209191-21-071172 9441
2021-12-23 4 FORM 4 SUBMISSION 0001209191-21-071170 7239
2021-12-23 4 FORM 4 SUBMISSION 0001209191-21-071169 9432
2021-12-23 4 FORM 4 SUBMISSION 0001209191-21-071168 7225
2021-12-23 4 FORM 4 SUBMISSION 0001209191-21-071167 7245
2021-12-09 8-K 8-K 8.01,9.01 0001564590-21-059819 001-33221 211480314 34 203800 1 1
2021-11-18 8-K 8-K 8.01,9.01 0001564590-21-057541 001-33221 211422614 34 189768 1 1
2021-11-03 10-Q 10-Q 0001564590-21-053953 001-33221 211375453 34 8010261 1 1
2021-11-03 8-K 8-K 2.02,9.01 0001564590-21-053940 001-33221 211375324 34 540310 1 1
2021-10-15 4 FORM 4 SUBMISSION 0001209191-21-060553 14196
2021-10-15 4 FORM 4 SUBMISSION 0001209191-21-060551 14187
2021-10-15 4 FORM 4 SUBMISSION 0001209191-21-060550 14146
2021-10-15 4 FORM 4 SUBMISSION 0001209191-21-060549 14107
2021-10-15 4 FORM 4 SUBMISSION 0001209191-21-060547 14179
2021-10-04 8-K 8-K 8.01,9.01 0001564590-21-049889 001-33221 211301137 34 199609 1 1
2021-09-29 3 FORM 3 SUBMISSION 0001209191-21-058056 7775
2021-09-29 3 FORM 3 SUBMISSION 0001209191-21-058054 7769
2021-09-24 8-K 8-K 5.02 0001564590-21-048772 001-33221 211274096 34 171122 1 1
2021-09-23 4 FORM 4 SUBMISSION 0001209191-21-057420 5363
2021-09-23 4 FORM 4 SUBMISSION 0001209191-21-057419 5361
2021-09-14 S-8 S-8 0001564590-21-047901 333-259518 211252738 33 283746
2021-08-30 UPLOAD filename1.pdf 0000000000-21-010556 39769
2021-08-10 CORRESP filename1.htm 0001564590-21-043096 57565
2021-08-09 10-Q 10-Q 0001564590-21-042362 001-33221 211154731 34 7684993 1 1
2021-08-09 8-K 8-K 2.02,9.01 0001564590-21-042359 001-33221 211154716 34 529342 1 1
2021-08-02 8-K 8-K 4.01,9.01 0001564590-21-039796 001-33221 211136425 34 171493 1 1
2021-07-15 4 FORM 4 SUBMISSION 0001209191-21-046791 10765
2021-07-15 4 FORM 4 SUBMISSION 0001209191-21-046790 10750
2021-07-15 4 FORM 4 SUBMISSION 0001209191-21-046789 10715
2021-07-15 4 FORM 4 SUBMISSION 0001209191-21-046788 10677
2021-07-15 4 FORM 4 SUBMISSION 0001209191-21-046786 9032
2021-07-15 UPLOAD filename1.pdf 0000000000-21-008767 47684
2021-06-22 4 FORM 4 SUBMISSION 0001209191-21-042433 5211
2021-06-22 4 FORM 4 SUBMISSION 0001209191-21-042429 5200
2021-06-17 8-K 8-K 5.07 0001564590-21-033349 001-33221 211024723 34 206353 1 1
2021-05-28 S-3ASR S-3ASR 0001193125-21-176988 333-256620 21980475 33 258112
2021-05-25 8-K 8-K 1.01,2.03,3.02,9.01 0001564590-21-029621 001-33221 21958236 34 844727 1 1
2021-05-13 8-K 8-K 8.01,9.01 0001564590-21-027241 001-33221 21917331 34 11162698 1 1
2021-05-10 10-Q 10-Q 0001564590-21-025796 001-33221 21905401 34 6902636 1 1
2021-05-10 8-K 8-K 2.02,9.01 0001564590-21-025793 001-33221 21905388 34 478806 1 1
2021-05-04 4 FORM 4 SUBMISSION 0001209191-21-030014 7011
2021-04-22 DEFA14A DEFA14A 0001564590-21-020111 001-33221 21844964 34 2124386
2021-04-22 DEF 14A DEF 14A 0001564590-21-020104 001-33221 21844804 34 2559108
2021-04-16 4 FORM 4 SUBMISSION 0001209191-21-027119 5211
2021-04-15 4 FORM 4 SUBMISSION 0001209191-21-026845 9047
2021-04-15 4 FORM 4 SUBMISSION 0001209191-21-026844 14406
2021-04-15 4 FORM 4 SUBMISSION 0001209191-21-026843 8998

Latest XBRL company facts

One latest value per concept from companyfacts (367 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 190.27M 2026-11-04 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
dei EntityPublicFloat Entity Public Float USD 235.10M 2025-06-30 2025 FY 10-K 2026-02-26 0001193125-26-073515
ecd CoSelectedMeasureAmt CoSelectedMeasureAmt USD 155.00M 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001193125-26-196306
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD 1.74M 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001193125-26-196306
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 2.54M 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001193125-26-196306
ecd PeerGroupTotalShareholderRtnAmt PeerGroupTotalShareholderRtnAmt USD 119.92 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001193125-26-196306
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 6.14 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001193125-26-196306
ffd NetFeeAmt NetFeeAmt USD 739.43 2026-10-26 S-8 2026-10-27 0001193125-26-434429
ffd TtlFeeAmt TtlFeeAmt USD 739.43 2026-10-26 S-8 2026-10-27 0001193125-26-434429
ffd TtlOfferingAmt TtlOfferingAmt USD 8.50M 2026-10-26 S-8 2026-10-27 0001193125-26-434429
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-10-26 S-8 2026-10-27 0001193125-26-434429
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 8.38M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap AccountsPayableOtherCurrent Accounts Payable, Other, Current USD 559,000 2023-12-31 2024 FY 10-K 2025-02-27 0000950170-25-028374
us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current USD 86.73M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 403,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap AccruedBonusesCurrent Accrued Bonuses, Current USD 6.46M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 2.62M 2014-03-31 2014 Q1 10-Q 2014-05-12 0001193125-14-194964
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 2.71M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap AccruedRentCurrent Accrued Rent, Current USD 780,000 2018-12-31 2019 FY 10-K 2020-03-02 0001564590-20-007973
us-gaap AccruedSalaries Accrued Salaries (Deprecated 2009-01-31) USD 401,000 2012-12-31 2012 FY 10-K 2013-03-01 0001193125-13-085823
us-gaap AccruedSalariesCurrent Accrued Salaries, Current USD 656,000 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap AccruedVacationCurrent Accrued Vacation, Current USD 2.16M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 12.88M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -7,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 1.96B 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature USD 230,000 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010603
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 3.08M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition USD 98,000 2011-01-01 2011-12-31 2012 FY 10-K 2013-03-01 0001193125-13-085823
us-gaap AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD 10.89M 2013-01-01 2013-12-31 2013 FY 10-K 2014-03-07 0001193125-14-087658
us-gaap AdjustmentsToAdditionalPaidInCapitalWarrantIssued Adjustments to Additional Paid in Capital, Warrant Issued USD 371,000 2023-01-01 2023-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 9.24M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap AllowanceForDoubtfulAccountsReceivable Accounts Receivable, Allowance for Credit Loss USD 0 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap AmortizationOfDebtDiscountPremium Amortization of Debt Discount (Premium) USD 734,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap AmortizationOfFinancingCosts Amortization of Debt Issuance Costs USD 73,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap AssetImpairmentCharges Asset Impairment Charges USD 4.27M 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-12 0000950170-24-124698
us-gaap Assets Assets USD 230.45M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap AssetsCurrent Assets, Current USD 209.11M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap AssetsFairValueDisclosureRecurring Assets, Fair Value Disclosure, Recurring (Deprecated 2018-01-31) USD 49.22M 2016-12-31 2016 FY 10-K 2017-02-23 0001193125-17-054088
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 4,000 2025-12-31 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 7,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 11.86M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap AvailableForSaleSecurities Available-for-sale Securities USD 67.36M 2018-03-31 2018 Q1 10-Q 2018-05-10 0001193125-18-158506
us-gaap AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax USD 5,000 2018-12-31 2018 FY 10-K 2019-02-22 0001193125-19-047780
us-gaap AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax USD 92,000 2018-12-31 2018 FY 10-K 2019-02-22 0001193125-19-047780
us-gaap AvailableForSaleSecuritiesAmortizedCost Available-for-sale Securities, Amortized Cost Basis USD 300.62M 2018-12-31 2018 FY 10-K 2019-02-22 0001193125-19-047780
us-gaap AvailableForSaleSecuritiesCurrent Available-for-sale Securities, Current USD 222.97M 2019-06-30 2019 Q2 10-Q 2019-08-05 0001564590-19-028537
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 11.85M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrent Debt Securities, Available-for-sale, Current USD 11.85M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap AvailableForSaleSecuritiesGrossRealizedGains Available-for-sale Securities, Gross Realized Gains USD 0 2018-01-01 2018-12-31 2018 FY 10-K 2019-02-22 0001193125-19-047780
us-gaap AvailableForSaleSecuritiesGrossRealizedLosses Available-for-sale Securities, Gross Realized Losses USD 0 2018-01-01 2018-12-31 2018 FY 10-K 2019-02-22 0001193125-19-047780
us-gaap AvailableForSaleSecuritiesGrossUnrealizedGains Available-for-sale Securities, Gross Unrealized Gain USD 7,000 2017-01-01 2017-12-31 2017 FY 10-K 2018-02-27 0001193125-18-060951
us-gaap AvailableForSaleSecuritiesGrossUnrealizedLoss Available-for-sale Securities, Gross Unrealized Loss USD 10,000 2017-01-01 2017-12-31 2017 FY 10-K 2018-02-27 0001193125-18-060951
us-gaap Cash Cash USD 83.50M 2022-06-30 2022 Q2 10-Q 2022-08-09 0001564590-22-028599
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 11.60M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap CashAndCashEquivalentsPeriodIncreaseDecrease Cash and Cash Equivalents, Period Increase (Decrease) USD 21.20M 2019-01-01 2019-06-30 2019 Q2 10-Q 2019-08-05 0001564590-19-028537
us-gaap CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments USD 23.40M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 11.60M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -17.05M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap CashEquivalentsAtCarryingValue Cash Equivalents, at Carrying Value USD 3.60M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights Class of Warrant or Right, Exercise Price of Warrants or Rights (Deprecated 2014-01-31) USD/shares_unit 4.35 2013-12-31 2013 FY 10-K 2014-03-07 0001193125-14-087658
us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights shares 220,164 2020-12-31 2020 FY 10-K 2021-02-24 0001564590-21-007841
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 61.67M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 1 2026-06-25 2026 Q2 10-Q 2026-08-10 0001193125-26-341301
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 400.00M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 188.31M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 188.31M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap CommonStockValue Common Stock, Value, Issued USD 1.90M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -18.62M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest USD 15.60M 2012-01-01 2012-09-30 2012 Q3 10-Q 2012-11-05 0001193125-12-451641
us-gaap ConstructionInProgressGross Construction in Progress, Gross USD 1.70M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap ContractsRevenue Contracts Revenue (Deprecated 2018-01-31) USD 0 2013-10-01 2013-12-31 2013 FY 10-K 2014-03-07 0001193125-14-087658
us-gaap ContractWithCustomerLiabilityCurrent Contract with Customer, Liability, Current USD 2.76M 2017-12-31 2019 FY 10-K 2020-03-02 0001564590-20-007973
us-gaap ConvertibleLongTermNotesPayable Convertible Notes Payable, Noncurrent USD 34.38M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap ConvertibleNotesPayable Convertible Notes Payable USD 64,000 2011-09-30 2011 Q3 10-Q 2011-11-07 0001193125-11-299888
us-gaap ConvertibleNotesPayableCurrent Convertible Notes Payable, Current USD 149.81M 2025-06-30 2025 Q2 10-Q 2025-08-08 0000950170-25-105475
us-gaap CostOfGoodsAndServicesSold Cost of Goods and Services Sold USD 31.17M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap CostOfGoodsSold Cost of Goods Sold (Deprecated 2018-01-31) USD 4.59M 2017-01-01 2017-12-31 2017 FY 10-K 2018-02-27 0001193125-18-060951
us-gaap CostsAndExpenses Costs and Expenses USD 84.94M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption Cumulative Effect of New Accounting Principle in Period of Adoption (Deprecated 2020-01-31) USD 1.57M 2017-12-31 2019 FY 10-K 2020-03-02 0001564590-20-007973
us-gaap DebtInstrumentConvertibleBeneficialConversionFeature Debt Instrument, Convertible, Beneficial Conversion Feature USD 369,000 2017-01-01 2017-12-31 2017 FY 10-K 2018-02-27 0001193125-18-060951
us-gaap DebtInstrumentFaceAmount Debt Instrument, Face Amount USD 4.67M 2012-09-30 2012 Q3 10-Q 2012-11-05 0001193125-12-451641
us-gaap DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage pure 0.1 2023-08-15 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap DebtInstrumentUnamortizedDiscount Debt Instrument, Unamortized Discount USD 78,000 2014-09-30 2014 Q3 10-Q 2014-11-06 0001193125-14-400994
us-gaap DebtSecuritiesAvailableForSaleRealizedGainLoss Debt Securities, Available-for-sale, Realized Gain (Loss) USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap DebtSecuritiesAvailableForSaleUnrealizedGainLoss Debt Securities, Available-for-sale, Unrealized Gain (Loss) USD -9,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 0 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap DeferredRevenueCurrent Deferred Revenue, Current USD 2.76M 2017-12-31 2018 Q3 10-Q 2018-11-07 0001193125-18-320941
us-gaap DeferredRevenueNoncurrent Deferred Revenue, Noncurrent USD 35,000 2010-12-31 2011 FY 10-K 2012-03-26 0001193125-12-132146
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 415.00M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 0 2015-12-31 2015 FY 10-K 2016-02-19 0001193125-16-469890
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 0 2013-12-31 2013 FY 10-K 2014-03-07 0001193125-14-087658
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 329.40M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsDomestic Deferred Tax Assets, Operating Loss Carryforwards, Domestic USD 35.10M 2012-12-31 2012 FY 10-K 2013-03-01 0001193125-13-085823
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal Deferred Tax Assets, Operating Loss Carryforwards, State and Local USD 34.10M 2012-12-31 2012 FY 10-K 2013-03-01 0001193125-13-085823
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 6.64M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap DeferredTaxAssetsTaxCreditCarryforwards Deferred Tax Assets, Tax Credit Carryforwards USD 19.20M 2012-12-31 2012 FY 10-K 2013-03-01 0001193125-13-085823
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsOther Deferred Tax Assets, Tax Credit Carryforwards, Other USD 400,000 2012-12-31 2012 FY 10-K 2013-03-01 0001193125-13-085823
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 57.02M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 3.98M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 415.00M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap DefinedBenefitPlanContributionsByEmployer Defined Benefit Plan, Plan Assets, Contributions by Employer USD 134,000 2013-01-01 2013-12-31 2013 FY 10-K 2014-03-07 0001193125-14-087658
us-gaap DefinedContributionPlanCostRecognized Defined Contribution Plan, Cost USD 800,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount USD 0 2013-01-01 2015-12-31 2015 FY 10-K 2016-02-19 0001193125-16-469890
us-gaap DefinedContributionPlanEmployerMatchingContributionPercent Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay pure 0.03 2013-01-01 2013-12-31 2013 FY 10-K 2014-03-07 0001193125-14-087658
us-gaap DefinedContributionPlanEmployerMatchingContributionPercentOfMatch Defined Contribution Plan, Employer Matching Contribution, Percent of Match pure 0.5 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap Depreciation Depreciation USD 1.50M 2018-01-01 2018-12-31 2018 FY 10-K 2019-02-22 0001193125-19-047780
us-gaap DepreciationAndAmortization Depreciation, Depletion and Amortization, Nonproduction USD 741,000 2017-01-01 2017-06-30 2017 Q2 10-Q 2017-08-09 0001193125-17-252860
us-gaap DepreciationDepletionAndAmortization Depreciation, Depletion and Amortization USD 1.37M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap DepreciationExpense Depreciation Expense (Deprecated 2009-01-31) USD 197,000 2012-01-01 2012-12-31 2012 FY 10-K 2013-03-01 0001193125-13-085823
us-gaap DisposalGroupIncludingDiscontinuedOperationRevenue Disposal Group, Including Discontinued Operation, Revenue USD 0 2012-01-01 2013-12-31 2013 FY 10-K 2014-03-07 0001193125-14-087658
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -0.1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -0.63 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-09 0001564590-22-018877
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -0.1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure 0.081 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.283 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent pure -0.007 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 8.84M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount USD 22.80M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsOnNonvestedAwards Employee Service Share-based Compensation, Unrecognized Compensation Costs on Nonvested Awards (Deprecated 2011-01-31) USD 21.10M 2012-12-31 2012 FY 10-K 2013-03-01 0001193125-13-085823
us-gaap EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsOnNonvestedAwardsWeightedAveragePeriodOfRecognition Employee Service Share-based Compensation, Unrecognized Compensation Costs on Nonvested Awards, Weighted Average Period of Recognition (Deprecated 2011-01-31) pure 2.9 2012-01-01 2012-12-31 2012 FY 10-K 2013-03-01 0001193125-13-085823
us-gaap EquityIssuancePerShareAmount Development Stage Entities, Equity Issuance, Per Share Amount (Deprecated 2015-01-31) USD 0.525 2012-07-01 2012-07-30 2012 Q2 10-Q 2012-08-09 0001193125-12-346661
us-gaap FixturesAndEquipmentGross Fixtures and Equipment, Gross USD 4.04M 2012-12-31 2012 FY 10-K 2013-03-01 0001193125-13-085823
us-gaap GainLossOnDispositionOfAssets Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property USD 4,000 2010-01-01 2010-12-31 2011 FY 10-K 2012-03-26 0001193125-12-132146
us-gaap GainLossOnDispositionOfProperty Gain (Loss) on Disposition of Property (Deprecated 2013-01-31) USD 4,000 2010-01-01 2010-12-31 2012 FY 10-K 2013-03-01 0001193125-13-085823
us-gaap GainLossOnSaleOfInterestInProjects Gain (Loss) on Sale of Interest in Projects USD 2.50M 2010-01-01 2010-12-31 2012 FY 10-K 2013-03-01 0001193125-13-085823
us-gaap GainLossOnSaleOfPropertyPlantEquipment Gain (Loss) on Disposition of Property Plant Equipment USD 0 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-10 0001193125-26-341301
us-gaap GainsLossesOnExtinguishmentOfDebt Gain (Loss) on Extinguishment of Debt USD -11.34M 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 35.76M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap GrossProfit Gross Profit USD 76.46M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap GuaranteedBenefitsIncurred Guaranteed Benefits Incurred (Deprecated 2013-01-31) USD 944,000 2000-07-01 2007-06-30 2012 FY 10-K 2013-03-01 0001193125-13-085823
us-gaap IncomeLossFromContinuingOperations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent USD -51.31M 2018-10-01 2018-12-31 2018 FY 10-K 2019-02-22 0001193125-19-047780
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -4.83M 2012-01-01 2012-03-31 2012 Q1 10-Q 2012-05-10 0001193125-12-224867
us-gaap IncomeLossFromContinuingOperationsPerBasicAndDilutedShare Income (Loss) from Continuing Operations, Per Basic and Diluted Share USD/shares -2.87 2014-01-01 2014-12-31 2014 FY 10-K 2015-03-13 0001193125-15-091072
us-gaap IncomeLossFromDiscontinuedOperationsNetOfTax Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest USD 1.09M 2012-10-01 2012-12-31 2013 FY 10-K 2014-03-07 0001193125-14-087658
us-gaap IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent USD 1.08M 2012-01-01 2012-12-31 2014 FY 10-K 2015-03-13 0001193125-15-091072
us-gaap IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share USD/shares 0 2013-01-01 2013-12-31 2013 FY 10-K 2014-03-07 0001193125-14-087658
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD -1.63M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap IncomeTaxReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount USD 74.36M 2017-01-01 2017-12-31 2019 FY 10-K 2020-03-02 0001564590-20-007973
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -4.24M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 5.70M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD 210,000 2012-01-01 2012-12-31 2012 FY 10-K 2013-03-01 0001193125-13-085823
us-gaap IncomeTaxReconciliationOtherReconcilingItems Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount USD 146,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-27 0000950170-25-028374
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD -619,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD -2.85M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap IncreaseDecreaseInAccruedLiabilities Increase (Decrease) in Accrued Liabilities USD -2.01M 2014-01-01 2014-03-31 2014 Q1 10-Q 2014-05-12 0001193125-14-194964
us-gaap IncreaseDecreaseInContractWithCustomerLiability Increase (Decrease) in Contract with Customer, Liability USD 1.66M 2017-01-01 2017-12-31 2019 FY 10-K 2020-03-02 0001564590-20-007973
us-gaap IncreaseDecreaseInDeferredRevenue Increase (Decrease) in Deferred Revenue USD 4.46M 2017-01-01 2017-09-30 2018 Q3 10-Q 2018-11-07 0001193125-18-320941
us-gaap IncreaseDecreaseInEmployeeRelatedLiabilities Increase (Decrease) in Employee Related Liabilities USD -434,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap IncreaseDecreaseInInventories Increase (Decrease) in Inventories USD 1.59M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap IncreaseDecreaseInOtherAccruedLiabilities Increase (Decrease) in Other Accrued Liabilities USD 3.71M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap IncreaseDecreaseInOtherNoncurrentAssets Increase (Decrease) in Other Noncurrent Assets USD 77,000 2011-01-01 2011-12-31 2013 FY 10-K 2014-03-07 0001193125-14-087658
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD -1.92M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap IncrementalCommonSharesAttributableToCallOptionsAndWarrants Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants shares 298,000 2025-01-01 2025-06-30 2026 Q2 10-Q 2026-08-10 0001193125-26-341301
us-gaap IncrementalCommonSharesAttributableToConversionOfDebtSecurities Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities shares 9.82M 2025-01-01 2025-06-30 2026 Q2 10-Q 2026-08-10 0001193125-26-341301
us-gaap IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements shares 29.70M 2025-01-01 2025-06-30 2026 Q2 10-Q 2026-08-10 0001193125-26-341301
us-gaap InterestExpense Interest Expense USD 3.87M 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-12 0000950170-24-029951
us-gaap InterestExpenseDebtExcludingAmortization Interest Expense, Debt, Excluding Amortization USD 200,000 2017-01-01 2017-06-30 2017 Q2 10-Q 2017-08-09 0001193125-17-252860
us-gaap InterestExpenseNonoperating InterestExpenseNonoperating USD 9.61M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap InterestIncomeExpenseNet Interest Income (Expense), Net USD -293,000 2016-01-01 2016-06-30 2016 Q2 10-Q 2016-08-08 0001193125-16-675250
us-gaap InterestIncomeExpenseNonoperatingNet Interest Income (Expense), Nonoperating, Net USD -2.33M 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-06 0001193125-17-333663
us-gaap InterestPaid Interest Paid, Including Capitalized Interest, Operating and Investing Activities USD 2.29M 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-06 0001193125-17-333663
us-gaap InterestPaidNet Interest Paid, Excluding Capitalized Interest, Operating Activities USD 7.97M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap InterestPayableCurrent Interest Payable, Current USD 904,000 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap InterestReceivableCurrent Interest Receivable, Current USD 160,000 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap InventoryFinishedGoodsNetOfReserves Inventory, Finished Goods, Net of Reserves USD 14.68M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap InventoryNet Inventory, Net USD 91.30M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap InventoryRawMaterialsNetOfReserves Inventory, Raw Materials, Net of Reserves USD 57.30M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap InventoryWorkInProcessNetOfReserves Inventory, Work in Process, Net of Reserves USD 19.32M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap InvestmentIncomeInterest Investment Income, Interest USD 1.95M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap LeaseAndRentalExpense Operating Leases, Rent Expense USD 3.20M 2018-01-01 2018-12-31 2018 FY 10-K 2019-02-22 0001193125-19-047780
us-gaap LeaseholdImprovementsGross Leasehold Improvements, Gross USD 1.35M 2012-12-31 2012 FY 10-K 2013-03-01 0001193125-13-085823
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 5.98M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five USD 3.10M 2019-12-31 2019 FY 10-K 2020-03-02 0001564590-20-007973
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 4.38M 2020-03-31 2020 Q1 10-Q 2020-05-06 0001564590-20-021575
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five USD 4.38M 2020-12-31 2020 FY 10-K 2021-02-24 0001564590-21-007841
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four USD 3.10M 2021-12-31 2021 FY 10-K 2022-02-28 0001564590-22-007618
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three USD 3.10M 2022-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010603
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two USD 3.14M 2023-12-31 2023 FY 10-K 2024-03-12 0000950170-24-029951
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months USD 3.14M 2024-12-31 2024 FY 10-K 2025-02-27 0000950170-25-028374
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 576,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 4.27M 2020-03-31 2020 Q1 10-Q 2020-05-06 0001564590-20-021575
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 685,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 665,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 646,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 0 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 266,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap Liabilities Liabilities USD 225.53M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 230.45M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap LiabilitiesCurrent Liabilities, Current USD 89.85M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap LiabilitiesForGuaranteesOnLongDurationContractsBenefitsPaid Liabilities for Guarantees on Long-Duration Contracts, Benefits Paid (Deprecated 2016-01-31) USD 944,000 2000-07-01 2007-06-30 2013 FY 10-K 2014-03-07 0001193125-14-087658
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD -18.39M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap NetCashProvidedByUsedInFinancingActivitiesContinuingOperations Net Cash Provided by (Used in) Financing Activities, Continuing Operations USD 141.98M 2017-01-01 2017-06-30 2017 Q2 10-Q 2017-08-09 0001193125-17-252860
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD 5.89M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Net Cash Provided by (Used in) Investing Activities, Continuing Operations USD -42.51M 2017-01-01 2017-06-30 2017 Q2 10-Q 2017-08-09 0001193125-17-252860
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -4.55M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Net Cash Provided by (Used in) Operating Activities, Continuing Operations USD -82.61M 2017-01-01 2017-06-30 2017 Q2 10-Q 2017-08-09 0001193125-17-252860
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -18.61M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap NetIncomeLossAvailableToCommonStockholdersDiluted Net Income (Loss) Available to Common Stockholders, Diluted USD 254,000 2025-01-01 2025-06-30 2026 Q2 10-Q 2026-08-10 0001193125-26-341301
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD -17.66M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap NotesPayableRelatedPartiesClassifiedCurrent Notes Payable, Related Parties, Current USD 25.00M 2017-12-31 2018 FY 10-K 2019-02-22 0001193125-19-047780
us-gaap NotesPayableRelatedPartiesNoncurrent Notes Payable, Related Parties, Noncurrent USD 50.00M 2016-12-31 2017 FY 10-K 2018-02-27 0001193125-18-060951
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-12 0000950170-24-029951
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap OperatingExpenses Operating Expenses USD 96.30M 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-05-09 0001193125-19-142333
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -8.48M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap OperatingLeaseExpense Operating Lease, Expense USD 3.10M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 5.72M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 359,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 5.36M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap OperatingLeasePayments Operating Lease, Payments USD 3.20M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 5.45M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 17.84M 2018-12-31 2018 FY 10-K 2019-02-22 0001193125-19-047780
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 3.19M 2018-12-31 2018 FY 10-K 2019-02-22 0001193125-19-047780
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFiveYears Operating Leases, Future Minimum Payments, Due in Five Years USD 2.97M 2018-12-31 2018 FY 10-K 2019-02-22 0001193125-19-047780
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFourYears Operating Leases, Future Minimum Payments, Due in Four Years USD 2.88M 2018-12-31 2018 FY 10-K 2019-02-22 0001193125-19-047780
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 2.80M 2018-12-31 2018 FY 10-K 2019-02-22 0001193125-19-047780
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 2.72M 2018-12-31 2018 FY 10-K 2019-02-22 0001193125-19-047780
us-gaap OperatingLeasesFutureMinimumPaymentsDueThereafter Operating Leases, Future Minimum Payments, Due Thereafter USD 3.27M 2018-12-31 2018 FY 10-K 2019-02-22 0001193125-19-047780
us-gaap OperatingLeasesRentExpense Operating Lease, Rent Expense (Deprecated 2009-01-31) USD 580,000 2012-01-01 2012-12-31 2012 FY 10-K 2013-03-01 0001193125-13-085823
us-gaap OperatingLeasesRentExpenseNet Operating Leases, Rent Expense, Net USD 967,000 2013-01-01 2013-12-31 2013 FY 10-K 2014-03-07 0001193125-14-087658
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 52.17M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 4.81M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap OtherComprehensiveIncomeLossNetOfTax Other Comprehensive Income (Loss), Net of Tax USD -55.30M 2013-01-01 2013-12-31 2013 FY 10-K 2014-03-07 0001193125-14-087658
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD -11,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap OtherIncome Other Income USD -599,000 2012-01-01 2012-12-31 2012 FY 10-K 2013-03-01 0001193125-13-085823
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 4.31M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap OtherNonoperatingExpense Other Nonoperating Expense USD 677,000 2014-01-01 2014-09-30 2014 Q3 10-Q 2014-11-06 0001193125-14-400994
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD -10.13M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap OtherNonrecurringIncomeExpense Other Nonrecurring (Income) Expense USD -240,000 2010-01-01 2010-12-31 2011 FY 10-K 2012-03-26 0001193125-12-132146
us-gaap OtherReceivablesNetCurrent Other Receivables, Net, Current USD 344,000 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap OtherSundryLiabilitiesCurrent Other Sundry Liabilities, Current USD 1.63M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale USD 0 2024-01-01 2024-03-31 2024 Q1 10-Q 2024-05-07 0000950170-24-053964
us-gaap PaidInKindInterest Paid-in-Kind Interest USD 2.60M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap PaymentsForProceedsFromInvestments Payments for (Proceeds from) Investments USD -52.69M 2017-01-01 2017-06-30 2017 Q2 10-Q 2017-08-09 0001193125-17-252860
us-gaap PaymentsForRestructuring Payments for Restructuring USD 5.40M 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010603
us-gaap PaymentsOfDebtExtinguishmentCosts Payment for Debt Extinguishment or Debt Prepayment Cost USD 25.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 1.53M 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap PaymentsToAcquireAvailableForSaleSecurities Payments to Acquire Available-for-sale Securities USD 127.76M 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-05-09 0001193125-19-142333
us-gaap PaymentsToAcquireAvailableForSaleSecuritiesDebt Payments to Acquire Debt Securities, Available-for-sale USD 33.90M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 631,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0.01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 2.50M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 70,012 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 70,012 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 1.05M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap PrepaidExpenseAndOtherAssets Prepaid Expense and Other Assets USD 14.51M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 7.63M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap PrepaidExpenseCurrent Prepaid Expense, Current USD 11.80M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap PrepaidInsurance Prepaid Insurance USD 1.96M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap ProceedsFromConvertibleDebt Proceeds from Convertible Debt USD 31.86M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap ProceedsFromDebtNetOfIssuanceCosts Proceeds from Debt, Net of Issuance Costs USD 1.30M 2011-04-01 2011-04-30 2012 Q3 10-Q 2012-11-05 0001193125-12-451641
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 19.84M 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap ProceedsFromIssuanceOfConvertiblePreferredStock Proceeds from Issuance of Convertible Preferred Stock USD 7.86M 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap ProceedsFromIssuanceOfDebt Proceeds from Issuance of Debt USD 3.00M 2012-05-01 2012-05-31 2012 Q3 10-Q 2012-11-05 0001193125-12-451641
us-gaap ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet Proceeds from Issuance of Long-term Debt and Capital Securities, Net USD 194.30M 2011-01-01 2015-03-31 2015 Q1 10-Q 2015-05-08 0001193125-15-179414
us-gaap ProceedsFromIssuanceOfPrivatePlacement Proceeds from Issuance of Private Placement USD 29.75M 2023-01-01 2023-09-30 2024 Q3 10-Q 2024-11-12 0000950170-24-124698
us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised USD 225,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised USD 883,000 2021-01-01 2021-03-31 2021 Q1 10-Q 2021-05-10 0001564590-21-025796
us-gaap ProceedsFromIssuanceOrSaleOfEquity Proceeds from Issuance or Sale of Equity USD 363.13M 2018-01-01 2018-06-30 2019 Q2 10-Q 2019-08-05 0001564590-19-028537
us-gaap ProceedsFromNotesPayable Proceeds from Notes Payable USD 105.38M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap ProceedsFromRelatedPartyDebt Proceeds from Related Party Debt USD 50.00M 2016-01-01 2016-12-31 2018 FY 10-K 2019-02-22 0001193125-19-047780
us-gaap ProceedsFromRepaymentsOfNotesPayable Proceeds from (Repayments of) Notes Payable USD 24.35M 2023-01-01 2023-12-31 2024 FY 10-K 2025-02-27 0000950170-25-028374
us-gaap ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities Proceeds from Sale and Maturity of Debt Securities, Available-for-sale USD 40.42M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap ProceedsFromSaleAndMaturityOfMarketableSecurities Proceeds from Sale and Maturity of Marketable Securities USD 614,000 2009-01-01 2009-12-31 2011 FY 10-K 2012-03-26 0001193125-12-132146
us-gaap ProceedsFromSaleOfPropertyPlantAndEquipment Proceeds from Sale of Property, Plant, and Equipment USD 82,000 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 5.70M 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-03 0001564590-21-053953
us-gaap ProceedsFromStockPlans Proceeds from Stock Plans USD 4.93M 2021-01-01 2021-12-31 2021 FY 10-K 2022-02-28 0001564590-22-007618
us-gaap ProceedsFromWarrantExercises Proceeds from Warrant Exercises USD 1,000 2023-01-01 2023-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap ProductionRelatedImpairmentsOrCharges Production Related Impairments or Charges USD 1.70M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -18.61M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 25.28M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 11.08M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap PurchaseObligation Purchase Obligation USD 19.00M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap PurchaseObligationDueInNextTwelveMonths Purchase Obligation, to be Paid, Year One USD 37.40M 2024-12-31 2024 FY 10-K 2025-02-27 0000950170-25-028374
us-gaap PurchaseObligationDueInSecondAndThirdYear Purchase Obligation, to be Paid, Year Two and Three USD 21.20M 2023-12-31 2023 FY 10-K 2024-03-12 0000950170-24-029951
us-gaap PurchaseObligationDueInSecondYear Purchase Obligation, to be Paid, Year Two USD 11.80M 2024-12-31 2024 FY 10-K 2025-02-27 0000950170-25-028374
us-gaap RepaymentsOfConvertibleDebt Repayments of Convertible Debt USD 125.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap RepaymentsOfLongTermDebt Repayments of Long-term Debt USD 25.00M 2018-01-01 2018-12-31 2018 FY 10-K 2019-02-22 0001193125-19-047780
us-gaap RepaymentsOfNotesPayable Repayments of Notes Payable USD 18.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 8.19M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap RestructuringAndRelatedCostExpectedCost1 Restructuring and Related Cost, Expected Cost USD 9.40M 2018-12-31 2019 FY 10-K 2020-03-02 0001564590-20-007973
us-gaap RestructuringAndRelatedCostExpectedCostRemaining1 Restructuring and Related Cost, Expected Cost Remaining USD 13.40M 2023-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap RestructuringCharges Restructuring Charges USD 5.40M 2022-06-01 2022-06-30 2024 FY 10-K 2025-02-27 0000950170-25-028374
us-gaap RestructuringReserveCurrent Restructuring Reserve, Current USD 1.09M 2017-12-31 2018 FY 10-K 2019-02-22 0001193125-19-047780
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -1.96B 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap RevenueFromContractWithCustomerIncludingAssessedTax Revenue from Contract with Customer, Including Assessed Tax USD 107.63M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 5.70M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap SalesAllowancesGoods Sales Allowances, Goods (Deprecated 2018-01-31) USD 342,000 2016-01-01 2016-12-31 2016 FY 10-K 2017-02-23 0001193125-17-054088
us-gaap SalesRevenueGoodsNet Sales Revenue, Goods, Net (Deprecated 2018-01-31) USD 30.77M 2017-01-01 2017-12-31 2017 FY 10-K 2018-02-27 0001193125-18-060951
us-gaap SellingAndMarketingExpense Selling and Marketing Expense USD 40.99M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 9.24M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date pure 0.85 2012-01-01 2012-09-30 2012 Q3 10-Q 2012-11-05 0001193125-12-451641
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2014-01-01 2014-03-31 2014 Q1 10-Q 2014-05-12 0001193125-14-194964
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 1.53 2014-01-01 2014-03-31 2014 Q1 10-Q 2014-05-12 0001193125-14-194964
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.02 2014-01-01 2014-03-31 2014 Q1 10-Q 2014-05-12 0001193125-14-194964
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number shares 3.80M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized shares 90.00M 2011-06-01 2011-06-30 2013 Q3 10-Q 2013-11-12 0001193125-13-437144
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized shares 95.00M 2011-06-30 2013 Q3 10-Q 2013-11-12 0001193125-13-437144
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant shares 8.49M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 200,000 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 11.81M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 4.64 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (Deprecated 2011-01-31) shares -37,786 2010-01-01 2010-12-31 2012 FY 10-K 2013-03-01 0001193125-13-085823
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 167,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period shares 528,773 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-02 0001564590-20-007973
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period shares 1.05M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price USD/shares 6.09 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 1.02M 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-02 0001564590-20-007973
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures shares 7.52M 2013-01-01 2013-03-31 2013 Q1 10-Q 2013-05-10 0001193125-13-213597
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 366,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 8.08 2013-01-01 2013-12-31 2013 FY 10-K 2014-03-07 0001193125-14-087658
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 385,000 2024-12-31 2024 FY 10-K 2025-02-27 0000950170-25-028374
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 28.02M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 2.84 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value USD 10.61M 2013-12-31 2013 FY 10-K 2014-03-07 0001193125-14-087658
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 28.70M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price USD/shares 2.98 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term (Deprecated 2012-01-31) Y 8.2 2012-01-01 2012-12-31 2012 FY 10-K 2013-03-01 0001193125-13-085823
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased USD/shares 0.21 2012-09-30 2012 Q3 10-Q 2012-11-05 0001193125-12-451641
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price USD/shares 27.81 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-02 0001564590-20-007973
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 20.91 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-02 0001564590-20-007973
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 0.99 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price USD/shares 4.64 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm1 Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term (Deprecated 2012-01-31) Y 7.13 2012-12-31 2012 FY 10-K 2013-03-01 0001193125-13-085823
us-gaap ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit USD/shares 5.2 2017-01-01 2017-12-31 2017 FY 10-K 2018-02-27 0001193125-18-060951
us-gaap ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable shares 11.81M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding shares 28.70M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price USD/shares 2.98 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm1 Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term (Deprecated 2012-01-31) Y 8.2 2012-12-31 2012 FY 10-K 2013-03-01 0001193125-13-085823
us-gaap ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit USD/shares 38.46 2017-01-01 2017-12-31 2017 FY 10-K 2018-02-27 0001193125-18-060951
us-gaap SharePrice Share Price USD/shares 0.525 2012-07-30 2012 Q3 10-Q 2012-11-05 0001193125-12-451641
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 4.92M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues shares 102.00M 2012-07-01 2012-07-30 2012 Q2 10-Q 2012-08-09 0001193125-12-346661
us-gaap StockIssuedDuringPeriodSharesShareBasedCompensationGross Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture shares 58,571 2012-01-01 2012-09-30 2012 Q3 10-Q 2012-11-05 0001193125-12-451641
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 7.88M 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010603
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 225,000 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 162.15M 2019-01-01 2019-12-31 2021 FY 10-K 2022-02-28 0001564590-22-007618
us-gaap StockIssuedDuringPeriodValueOther Stock Issued During Period, Value, Other USD 57.80M 2013-01-01 2013-12-31 2014 FY 10-K 2015-03-13 0001193125-15-091072
us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures Stock Issued During Period, Value, Restricted Stock Award, Forfeitures USD 98,000 2011-01-01 2011-12-31 2013 FY 10-K 2014-03-07 0001193125-14-087658
us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures USD 98,000 2011-01-01 2011-12-31 2012 FY 10-K 2013-03-01 0001193125-13-085823
us-gaap StockIssuedDuringPeriodValueShareBasedCompensation Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture USD -68,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 6.76M 2020-01-01 2020-12-31 2020 FY 10-K 2021-02-24 0001564590-21-007841
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 10.90M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions USD 0 2013-01-01 2013-12-31 2013 FY 10-K 2014-03-07 0001193125-14-087658
us-gaap UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued USD 0 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073515
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions USD 200,000 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010603
us-gaap UnrecognizedTaxBenefitsResultingInNetOperatingLossCarryforward Unrecognized Tax Benefits Resulting in Net Operating Loss Carryforward (Deprecated 2014-01-31) USD 13.90M 2012-12-31 2012 FY 10-K 2013-03-01 0001193125-13-085823
us-gaap UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate Unrecognized Tax Benefits that Would Impact Effective Tax Rate USD 100,000 2016-12-31 2017 FY 10-K 2018-02-27 0001193125-18-060951
us-gaap UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount Unrecorded Unconditional Purchase Obligation USD 35.90M 2017-12-31 2017 FY 10-K 2018-02-27 0001193125-18-060951
us-gaap ValuationAllowanceAmount Valuation Allowance, Amount (Deprecated 2013-01-31) USD -19.20M 2012-12-31 2012 FY 10-K 2013-03-01 0001193125-13-085823
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 55.20M 2016-01-01 2016-12-31 2016 FY 10-K 2017-02-23 0001193125-17-054088
us-gaap ValuationAllowancesAndReservesBalance SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount USD 47.73M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap ValuationAllowancesAndReservesDeductions SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction USD 198.16M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap ValuationAllowancesAndReservesPeriodIncreaseDecrease SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease) USD 8.90M 2012-01-01 2012-12-31 2012 FY 10-K 2013-03-01 0001193125-13-085823
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 190.31M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 102.12M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-09 0001564590-22-018877
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 190.31M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452759

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →